XML 30 R6.htm IDEA: XBRL DOCUMENT v3.25.2
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2023
Statement of cash flows [abstract]      
Net profit/(loss) $ 1,011,790 $ (51,159,048) $ (3,206,403)
Non-cash adjustment:      
Fair value (gain)/loss on convertible note (3,357,628) 5,157,397
Fair value (gain)/loss on warrant liability (694,516) 306,250
Fair value (gain)/loss on promissory notes (705,565) 300,270
Fair value loss on warrant exchange 185,064
Fair value gain on Psyence Labs Ltd (22,967)
Gain on debt settlement (281,500)
Share based compensation 317,882 221,287
Third party advisors share issuance 241,379
Depreciation 4,268 240
Foreign exchange (9,860) 3,660 (84,499)
Listing expense 41,481,605
Transaction expenses 2,100,830
Changes in working capital:      
Other receivables (95,601) 107,622 (109,858)
Prepaids 70,330 (245,075) (71,665)
Accounts payable and accrued liabilities (360,932) (1,035,498) 1,659,058
Cash used in operating activities (3,734,238) (2,945,365) (1,592,080)
Additions to equipment (9,877) (5,727)
Increase in restricted cash (6,353)
Cash used for investing activities (16,230) (5,727)
Proceeds received from convertible note 1,000,000 2,500,000
Payment of promissory note (150,000)
Proceeds received from Psyence Group Inc 1,172,923
Net proceeds received from ELOC 6,410,395
Net proceeds received for unit issuances 1,742,051
Cash provided from financing activities 9,152,446 2,350,000 1,172,923
Change in cash and cash equivalents 5,401,978 (601,092) (419,157)
Cash and cash equivalents, beginning of year 733,188 1,334,280 1,753,437
Cash and cash equivalents, end of year $ 6,135,166 $ 733,188 $ 1,334,280